Tag: RECIST 1.1

A narrative review indicates that FAPI PET is not yet a validated biomarker for assessing treatment response in radioiodine-refractory differentiated ...

A retrospective study of 60 Chinese patients with metastatic renal cell carcinoma receiving first-line ipilimumab plus nivolumab showed progression-free survival ...

A first-in-human trial of actinium-225-PSMA-CY313 demonstrated manageable salivary toxicity alongside preliminary biochemical and radiographic responses in heavily pretreated metastatic castration-resistant ...

A retrospective study of 112 patients with pancreatic ductal adenocarcinoma found that dual-energy computed tomography measurements of extracellular volume fraction ...

A retrospective study found that FAPI SPECT/CT imaging demonstrated superior sensitivity and accuracy compared to conventional computed tomography in detecting ...

A single-arm exploratory study reports an 88.2 percent 12-week objective response rate and preliminary two-year survival estimates for nimotuzumab added ...

A retrospective cohort study found that FDG-PET detected heterogeneous treatment responses in thirty percent of metastatic breast cancer follow-up examinations, ...

Depth of response and early tumor shrinkage serve as significant predictors of overall survival in patients receiving second-line or later ...

A case report describes a man with giant unresectable hepatocellular carcinoma whose inferior vena cava tumor thrombus regressed completely after ...

A retrospective single-center study found that at least 20% early tumor shrinkage was associated with longer progression-free survival after first-line ...